4.5 Article

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

Journal

ONCOTARGETS AND THERAPY
Volume 10, Issue -, Pages 2389-2401

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S126320

Keywords

oncolytic virus; vaccinia virus; immunogenic cell death; dendritic cells; cytotoxic T lymphocytes; immunotherapy

Ask authors/readers for more resources

Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/ hGM-CSF (JX-GFP) and TG6002 are genetically modified by secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) or transforming 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). We compared their properties to kill tumor cells and induce an immunogenic type of cell death in a human melanoma cell model using SK29-MEL melanoma cells. Their influence on human immune cells, specifically regarding the activation of dendritic cells (DCs) and the interaction with the autologous cytotoxic T lymphocyte (CTL) clone, was investigated. Melanoma cells were infected with either JX-GFP or TG6002 alone or in combination with 5-FC and 5-FU. The influence of viral infection on cell viability followed a time-and multiplicity of infection dependent manner. Combination of virus treatment with 5-FU resulted in stronger reduction of cell viability. TG6002 in combination with 5-FC did not significantly strengthen the reduction of cell viability in this setting. Expression of calreticulin and high mobility group 1 protein (HMGB1), markers of immunogenic cell death (ICD), could be detected after viral infection. Accordingly, DC maturation was noted after viral oncolysis. DCs presented stronger expression of activation and maturation markers. The autologous CTL clone IVSB expressed the activation marker CD69, but viral treatment failed to enhance cytotoxicity marker. In summary, vaccinia viruses JX-GFP and TG6002 lyse melanoma cells and induce additional immunostimulatory effects to promote antitumor immune response. Further investigation in vivo is needed to consolidate the data.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency

Marine Ricordel, Johann Foloppe, Delphine Antoine, Annie Findeli, Juliette Kempf, Pascale Cordier, Aude Gerbaud, Benoit Grellier, Monika Lusky, Eric Quemeneur, Philippe Erbs

CANCERS (2018)

Article Oncology

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns, Thomas Thomaidis

BMC CANCER (2019)

Article Oncology

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

J. W. Holch, I. Ricard, S. Stintzing, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, T. Heintges, C. Kahl, F. Kullmann, W. Scheithauer, M. Moehler, I. Jelas, D. P. Modest, C. B. Westphalen, J. C. von Einem, M. Michl, V. Heinemann

EUROPEAN JOURNAL OF CANCER (2019)

Article Oncology

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design

Markus Moehler, Min-Hee Ryu, Mikhail Dvorkin, Keun-Wook Lee, Hasan S. Coskun, Rachel Wong, Hyun C. Chung, Artem Poltoratsky, Akihito Tsuji, Chia Jui Yen, Alina S. Muntean, Samuel Le Sourd, Gina M. Vaccaro, Lindsay Overton, Narikazu Boku, Zev A. Wainberg, Manish Patel, Maitreyi Sharma, Huiling Xiong, Ilaria Conti, Julien Taieb, Yung-Jue Bang

FUTURE ONCOLOGY (2019)

Article Virology

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

Patricia Kleinpeter, Christelle Remy-Ziller, Eline Winter, Murielle Gantzer, Virginie Nourtier, Juliette Kempf, Julie Hortelano, Doris Schmitt, Huguette Schultz, Michel Geist, Catherine Brua, Chantal Hoffmann, Yasmin Schlesinger, Dominique Villeval, Christine Thioudellet, Philippe Erbs, Johann Foloppe, Nathalie Silvestre, Laetitia Fend, Eric Quemeneur, Jean-Baptiste Marchand

JOURNAL OF VIROLOGY (2019)

Article Oncology

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Johann Foloppe, Juliette Kempf, Nicolas Futin, Jacqueline Kintz, Pascale Cordier, Christelle Pichon, Annie Findeli, Fabien Vorburger, Eric Quemeneur, Philippe Erbs

MOLECULAR THERAPY-ONCOLYTICS (2019)

Article Oncology

Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy

Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath Singaravelu, Marian Hussein, Florian Gossart, Victoria A. Jennings, Lawton J. Stubbert, Madison Foster, Christopher Storbeck, Antonio Postigo, Elena Scut, Brian Laight, Michael Way, Philippe Erbs, Fabrice Le Boeuf, John C. Bell

MOLECULAR THERAPY-ONCOLYTICS (2019)

Article Veterinary Sciences

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

Jeremy Beguin, Virginie Nourtier, Murielle Gantzer, Sandrine Cochin, Johann Foloppe, Jean-Marc Balloul, Eve Laloy, Dominique Tierny, Bernard Klonjkowski, Eric Quemeneur, Christelle Maurey, Philippe Erbs

BMC VETERINARY RESEARCH (2020)

Article Oncology

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma

Tiphaine Delaunay, Joelle Nader, Marion Grard, Isabelle Farine, Vera Hedwig, Johann Foloppe, Thibaut Blondy, Mathilde Violland, Daniel Pouliquen, Marc Gregoire, Nicolas Boisgerault, Philippe Erbs, Jean-Francois Fonteneau

MOLECULAR THERAPY-ONCOLYTICS (2020)

Article Multidisciplinary Sciences

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jeremy Beguin, Murielle Gantzer, Isabelle Farine, Johann Foloppe, Bernard Klonjkowski, Christelle Maurey, Eric Quemeneur, Philippe Erbs

Summary: The study evaluated the safety, biodistribution, and shedding of TG6002, a recombinant oncolytic vaccinia virus, administered intravenously in immune-competent healthy dogs, showing a good safety profile and supporting its potential for clinical trials in canine cancer patients and further development as human cancer therapy.

SCIENTIFIC REPORTS (2021)

Article Oncology

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Jeremy Beguin, Johann Foloppe, Christelle Maurey, Eve Laloy, Julie Hortelano, Virginie Nourtier, Christelle Pichon, Sandrine Cochin, Pascale Cordier, Helene Huet, Eric Quemeneur, Bernard Klonjkowski, Philippe Erbs

MOLECULAR THERAPY-ONCOLYTICS (2020)

Article Biochemistry & Molecular Biology

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, Doris Schmitt, Renee Brandely, Catherine Brua, Nathalie Silvestre, Annie Findeli, Johann Foloppe, Sokunthea Top, Sandrine Kappler-Gratias, Charlotte Quentin-Froignant, Renaud Morin, Jean-Michel Lagarde, Kerstin Bystricky, Stephane Bertagnoli, Philippe Erbs

BIOMEDICINES (2020)

Article Veterinary Sciences

Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs

Jeremy Beguin, Matthias Kohlhauer, Eve Laloy, Frederique Degorce, Baptiste Moreau, Eric Quemeneur, Philippe Erbs, Bernard Klonjkowski, Christelle Maurey

Summary: Long-term administration of 5-fluorocytosine in healthy dogs resulted in cutaneous toxicity, indicating that pharmacotherapy should be adjusted to reduce toxicity in targeted chemotherapy.

BMC VETERINARY RESEARCH (2021)

Article Biophysics

Direct imaging and automatic analysis in tumor-on-chip reveal cooperative antitumoral activity of immune cells and oncolytic vaccinia virus

Arianna Mencattini, Christine Lansche, Irina Veith, Philippe Erbs, Jean-Marc Balloul, Eric Quemeneur, Stephanie Descroix, Fatima Mechta-Grigoriou, Gerard Zalcman, Cecile Zaupa, Maria Carla Parrini, Eugenio Martinelli

Summary: Organ-on-chip and tumor-on-chip microfluidic cell cultures are important for modeling organ functions, diseases, drug development, and personalized medicine. Analyzing the large amount of bio-images acquired in these 3D microenvironments is a challenge, which can be addressed by the interdisciplinary contributions of computer science and electronic engineering. In this study, we applied this approach to study the oncolytic vaccinia virus (OVV) in cancer immunotherapy, and found a synergistic cooperation between OVV and immune cells in killing cancer cells. We also observed changes in immune cell kinetics and a correlation between cancer cell infection and cancer-immune interaction time.

BIOSENSORS & BIOELECTRONICS (2022)

Article Immunology

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

Rodrigo Nalio Ramos, Caroline Tosch, Fiorella Kotsias, Marie-Christine Claudepierre, Doris Schmitt, Christelle Remy-Ziller, Chantal Hoffmann, Marine Ricordel, Virginie Nourtier, Isabelle Farine, Laurence Laruelle, Julie Hortelano, Clementine Spring-Giusti, Christine Sedlik, Christophe Le Tourneau, Caroline Hoffmann, Nathalie Silvestre, Philippe Erbs, Kaidre Bendjama, Christine Thioudellet, Eric Quemeneur, Eliane Piaggio, Karola Rittner

Summary: This study identifies bovine pseudocowpox virus (PCPV) as a viral vector with strong immune stimulating abilities, capable of activating immune cells and reversing tumor-induced T-cell suppression. Using PCPV encoding the HPV16 E7 protein as a vaccine, significant antigen-specific T-cell responses were induced in experimental tumor-bearing mice, resulting in complete tumor regression. From a translational perspective, PCPV-E7 effectively stimulated IFN-γ production by T cells from tumor-draining lymph nodes of HPV+-infected cancer patients.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)

No Data Available